![Catherine Madigan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Catherine Madigan
Chief Tech/Sci/R&D Officer at
HEMAB THERAPEUTICS HOLDINGS, INC.
Net worth: - $ as of 2026-07-30
Profile
Catherine Madigan is Chief Medical Officer at Hemab Therapeutics Holdings, Inc. since 2025.
Former positions include Senior Medical Director at Alnylam Pharmaceuticals, Inc., Vice President & Head-Clinical Development at Syros Pharmaceuticals, Inc., and Chief Medical Officer at Syndax Pharmaceuticals, Inc. from 2022 to 2024.
Education includes an undergraduate degree from Dartmouth College and a doctorate from Keck School of Medicine of USC.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-30 | 0 ( -.--% ) | - $ | 2026-07-30 |
Catherine Madigan active positions
| Companies | Position | Start |
|---|---|---|
| HEMAB THERAPEUTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 2024-12-31 |
Former positions of Catherine Madigan
| Companies | Position | End |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2024-12-19 |
| ALNYLAM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| SYROS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Catherine Madigan
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
7
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Dartmouth College
 Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Syros Pharmaceuticals, Inc.
 Syros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which developing care for the frontline treatment of patients with hematologic malignancies | Health Technology |
Keck School of Medicine of USC
 Keck School of Medicine of USC Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HEMAB THERAPEUTICS INC.
 HEMAB THERAPEUTICS INC. BiotechnologyHealth Technology Engages in research and development of prophylactic therapeutics for bleeding disorders | Health Technology |
- Stock Market
- Insiders
- Catherine Madigan
